| Title: | Evaluation of soluble mesothelin-related peptides and MSLN genetic variability in asbestos-related diseases |
|---|
| Authors: | ID Goričar, Katja (Author)
ID Kovač, Viljem (Author)
ID Dodič-Fikfak, Metoda (Author)
ID Dolžan, Vita (Author)
ID Franko, Alenka (Author) |
|---|
| Files: |  URL - Source URL, visit https://content.sciendo.com/view/journals/raon/54/1/article-p86.xml?tab_body=pdf-69320
 PDF - Presentation file, download (640,41 KB)
MD5: 01CC8C6E238AD275AAFD78F5F5BE1D38
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  OI - Institute of Oncology
|
|---|
| Abstract: | Background Asbestos exposure is associated with increased risk of several diseases, including malignant mesothelioma (MM). Cell surface glycoprotein mesothelin is overexpressed in MM and serum soluble mesothelin-related peptides (SMRP) were already proposed as a diagnostic or prognostic biomarker in MM. However, interindividual variability in serum SMRP levels limits the clinical usefulness. Our primary objective was to investigate the influence of MSLN rs1057147 on serum SMRP levels in asbestos-exposed subjects and patients with asbestos-related diseases as well as on survival in MM. Subjects and methods Among 782 asbestos-exposed subjects and patients with asbestos-related diseases, 154 had MM. Serum SMRP levels were determined using sandwich enzyme-linked immunosorbent assay. All subjects were genotyped for MSLN rs1057147 polymorphism using competitive allele-specific polymerase chain reaction. Nonparametric tests, logistic and Cox regression were used in statistical analysis to compare different subject groups. Results MM patients had significantly higher SMRP levels than all other subjects (p < 0.001). Compared to wild-type MSLN rs1057147 genotype, both heterozygotes and carriers of two polymorphic alleles had significantly higher SMRP levels among subjects without MM (p < 0.001), but not in MM patients (p = 0.424). If genotype information was included, specificity of SMRP increased from 88.5% to 92.7% for the optimal cutoff value. Overall survival was significantly shorter in MM patients carrying at least one polymorphic rs1057147 allele (HR = 1.72, 95% CI = 1.15-2.55, p = 0.008). Conclusions MSLN genetic variability affects serum SMRP levels and was associated with shorter survival of MM patients. Combination of genetic and serum factors could therefore serve as a better diagnostic or prognostic biomarker in MM patients. |
|---|
| Keywords: | asbestos-related disease, malignant mesothelioma, mesothelin |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Publication date: | 01.03.2020 |
|---|
| Publisher: | Association of Radiology and Oncology |
|---|
| Year of publishing: | 2020 |
|---|
| Number of pages: | str. 86-95, IX |
|---|
| Numbering: | Vol. 54, no. 1 |
|---|
| Source: | Ljubljana |
|---|
| PID: | 20.500.12556/DiRROS-19358  |
|---|
| UDC: | 616-057 |
|---|
| ISSN on article: | 1318-2099 |
|---|
| DOI: | 10.2478/raon-2020-0011 |
|---|
| COBISS.SI-ID: | 34748377 |
|---|
| Copyright: | by Authors |
|---|
| Note: | Soavtorji: Viljem Kovac, Metoda Dodic-Fikfak, Vita Dolzan and Alenka Franko;
|
|---|
| Publication date in DiRROS: | 16.07.2024 |
|---|
| Views: | 385 |
|---|
| Downloads: | 166 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
